Microbiome manipulation with faecal microbiome transplantation as a therapeutic strategy in Clostridium difficile infection

QJM: An International Journal of Medicine

Volumn 108, Issue 5, 2015, Pages 355-359

  Mullish, B H ^a   Marchesi, J R ^a   Thursz, M R ^a   Williams, H R T ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD ANALYSIS; CLINICAL EFFECTIVENESS; CLOSTRIDIUM DIFFICILE INFECTION; DIARRHEA; DISEASE TRANSMISSION; FECAL MICROBIOTA TRANSPLANTATION; FECES ANALYSIS; HUMAN; INTESTINE FLORA; NONHUMAN; PATIENT SAFETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; REVIEW; TOXIC MEGACOLON; ADVERSE EFFECTS; CLOSTRIDIUM INFECTIONS; DONOR SELECTION; MICROFLORA; PATHOGENICITY; PEPTOCLOSTRIDIUM DIFFICILE;

CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DONOR SELECTION; FECAL MICROBIOTA TRANSPLANTATION; HUMANS; MICROBIOTA;

EID: 84983135268     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcu182     Document Type: Review

References (25)

1. Lawley TD, Walker AW. Intestinal colonization resistance. Immunology 2013; 138:1-11.
2. Holmes E, Li JV, Athanasiou T, Ashrafian H, Nicholson JK. Understanding the role of gut microbiome-host metabolic signal disruption in health and disease. Trends Microbiol 2011; 19:349-59.
3. Freeman J, Bauer MP, Baines SD, Corver J, Fawley WN, Goorhuis B, et al. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010;23;529-49.
4. Khanna S, Pardi DS, Aronson SL, Kammer PP, Orenstein R, St Sauver JL, et al. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol 2012; 107:89-95.
5. Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108:478-98.
6. Kelly CR, Ihunnah C, Fischer M, Khoruts A, Surawicz C, Afzali A, et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol 2014; 109:1065-71.
7. Pépin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 2006;42;758-64.
8. McFarland LV, Surawicz CM, Rubin M, Fekety R, Elmer GW, Greenberg RN. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 1999; 20:43-50.
9. Hu MY, Katchar K, Kyne L, Maroo S, Tummala S, Dreisbach V, et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology 2009; 136:1206-14.
10. Brandt LJ, Aroniadias OC, Mellow M, Kanatzar A, Kelly C, Park T, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107:1079-87.
11. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368:407-15.
12. Bakken JS, Borody T, Brandt LJ, Brill JV, Demarco DC, Franzos MA, et al. Fecal Microbiota Transplantation Workgroup. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011; 9:1044-9.
13. Swaminath A. The power of poop: patients getting ahead of their doctors using self-administered fecal transplants. Am J Gastroenterol 2014; 109:777-8.
14. Hamilton MJ, Weingarden AR, Sadowsky MJ, Khoruts A. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107:761-7.
15. Youngster I, Sauk J, Pindar C, Wilson RG, Kaplan JL, Smith MB, et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis 2014; 58:1515-22.
16. Brandt LJ, Borody TJ, Campbell J. Endoscopic fecal microbiota transplantation: "first-line" treatment for severe Clostridium difficile infection? J Clin Gastroenterol 2011;45;655-7.
17. Weingarden AR, Hamilton MJ, Sadowsky MJ, Khoruts A. Resolution of severe Clostridium difficile infection following sequential fecal microbiota transplantation. J Clin Gastroenterol 2013; 47:735-7.
18. Konijeti GG, Sauk J, Shrime MG, Gupta M, Ananthakrishnan AN. Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis. Clin Infect Dis 2014; 58:1507-14.
19. National Institute for Health and Care Excellence. Faecal Microbiota Transplant for Recurrent Clostridium difficile Infection, IPG 485. London: National Institute for Health and Care Excellence, 2014.
20. Nicholson JK, Holmes E, Kinross J, Burcellin R, Gibson G, Jia W, et al. Host-gut microbiota metabolic interactions. Science 2012; 336:1262-7.
21. Ridura VK, Fiath JJ, Rey FE, Cheng J, Duncan AE, Kau AL, et al. Gut microbiota from twins discordant for obesity modulate metabolim in mice. Science 2013; 341:1241214.
22. Vrieze A, van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JFWM, et al. Insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012; 143:913-6.
23. Holmes E, Li JV, Marchesi JR, Nicholson JK. Gut microbiota composition and activity in relation to host metabolic phenotype and disease risk. Cell Metab 2012; 16:559-64.
24. Borody TJ, Brandt LJ, Paramsothy S. Therapeutic faecal microbiota transplantation: current status and future developments. Curr Opin Gastroenterol 2014; 30:97-105.
25. Petrof EO, Khoruts A. From stool transplants to next-generation microbiota therapeutics. Gastroenterology 2014;146;1573-82.